<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078294</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-DER-2021-01</org_study_id>
    <nct_id>NCT05078294</nct_id>
  </id_info>
  <brief_title>Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis</brief_title>
  <acronym>Dermatitis</acronym>
  <official_title>Results in Real Clinical Practice of Treatment With Patients With Moderate-severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy results in terms of percentage&#xD;
      improvement of the Eczema Area and Severity Index (EASI) as well as on the scale Patient&#xD;
      Global Assessment (PGA) throughout the follow-up of patients undergoing subjected to systemic&#xD;
      and/or biological treatments in conditions of usual clinical practice. Likewise, collect&#xD;
      safety data, recording adverse events related to medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observacional follow-up study, open-label (all people know the identity of the&#xD;
      intervention), prospective (study following participants forward in time), multi-center study&#xD;
      in adult participants with moderate to severe atopic dermatitis. A registration can also be&#xD;
      made retrospective data from the patient's medical history.&#xD;
&#xD;
      Participants will be treated with one of this therapy (phototherapy, cyclosporine,&#xD;
      methotrexate, azathioprine, mycophenolate, dupilumab, baricitinib, upadacitinib or&#xD;
      tralokilumab).&#xD;
&#xD;
      A series of variables will be measured (basal surface area affected (BSA), Eczema Area and&#xD;
      Severity Index (EASI), numbers of shoots, analytical determinations and current treatment and&#xD;
      adverse effects occurred) in order to observe the changes in the improvement of the disease.&#xD;
      Questionnaires will also be carried out to analyze whether the drug acts favorably in&#xD;
      improving the disease. Questionnaires like Dermatology Life Quality Index (DLQI), Patient&#xD;
      Global Assesment (PGA) and Patient Oriented SCOring Atopic Dermatitis (PO-SCORAD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who showed a change in disease severity.</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Percentage improvement in Eczema Area and Severity Index (EASI) throughout the follow-up of patients undergoing systemic treatments and/or biological.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication-related adverse effect rate.</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Number of adverse effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life parameters.</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Completion of the self-administered dermatology quality of life index questionnaire, which measures the quality of life of the patient.&#xD;
Numerical variable (range 0-30) obtained from a self-administered questionnaire already validated in Spanish, which measures the quality of life of surveyed, consisting of 10 questions.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients treated as monotherapy with phototherapy, cyclosporine, methotrexate, azathioprine, mycophenolate, dupilumab, baricitinib, upadacitinib, or tralokilumab for the treatment of moderate to severe atopic dermatitis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population would be patients older than 18 years who suffer from the disease and&#xD;
        are being treated with a systemic therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years.&#xD;
&#xD;
          -  Patients treated with any systemic therapy (other than topical therapy) according to&#xD;
             criteria clinical and routine clinical practice. Therefore, the treatments included&#xD;
             will be: phototherapy, cyclosporine, methotrexate, azathioprine, mycophenolate,&#xD;
             dupilumab, baricitinib, upadacitinib and tralokilumab.&#xD;
&#xD;
          -  Patients who grant informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not have the necessary comprehension capacity to understand and sign&#xD;
             the informed consent.&#xD;
&#xD;
          -  Patients who, according to routine clinical practice, require only topical treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Juan Pereyra Rodríguez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José Juan Pereyra Rodríguez</last_name>
    <phone>955 01 20 00</phone>
    <email>josej.pereyra.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 04 31 27</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guilabert Vidal</last_name>
      <phone>938 42 50 00</phone>
    </contact>
    <investigator>
      <last_name>Antonio Guilabert Vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Carlos Armario Hita</last_name>
      <phone>956 00 50 00</phone>
    </contact>
    <investigator>
      <last_name>José Carlos Armario Hita</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Elosua González</last_name>
      <phone>911 91 60 00</phone>
    </contact>
    <investigator>
      <last_name>Ángel Rosell Díaz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaston Roustan Gullón</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Francisco Silvestre Salvador</last_name>
      <phone>965 93 30 00</phone>
    </contact>
    <investigator>
      <last_name>Juan Francisco Silvestre Salvador</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Serra-Baldrich</last_name>
      <phone>93 291 90 00</phone>
    </contact>
    <investigator>
      <last_name>Esther Serra-Baldrich</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Flores</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Sánchez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Juan Pereyra Rodríguez</last_name>
      <phone>955 01 20 00</phone>
      <email>josej.pereyra.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>José Juan Pereyra Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Javier Miquel Miquel</last_name>
      <phone>961 97 60 00</phone>
    </contact>
    <investigator>
      <last_name>Francisco Javier Miquel Miquel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

